Q-omics provides the consensus-scored ZNF556 profile across patient tissues and cancer cell-line models. ZNF556 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF556 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, ZNF556 RNA expression shows 14,140 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUSC, and THYM as cancer lineages where ZNF556 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF556 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF556 survival associations across molecular data types. ZNF556 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF556 RNA expression–survival associations across cancer types. High ZNF556 expression shows unfavorable associations in COAD, but favorable associations in KIRP, SKCM, SCLC, MESO and THYM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF556 RNA expression.
This table summarizes ZNF556 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF556. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF556 shows lower tumor expression in KIRC and higher tumor expression in LUSC, BLCA, COAD, CHOL and STAD. The LUSC box plot shows higher ZNF556 RNA expression in tumor versus normal tissue (log2 FC = +0.991, t-test p < 0.001).
This table shows molecular features associated with ZNF556 in patient tissues and cancer cell lines. In patient samples, ZNF556 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF556 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
